I have a problem with YouTube addiction, which I am trying to manage. My problem is that YouTube has a great deal of content that I find interesting. I suppose that any form of entertainment is an escape from reality.
It's not you. Phones are designed to be addicting...
The following uses very crude language, but he is not wrong:
I'm not sure if this is helpful...
Biden must put jobs first and stop treating our domestic oil and gas producers as the enemies of progress. Oil and natural gas power our computers, our cars and trucks, our factories, our furnaces, our cellphones -- and all that our $22 trillion industrial economy encompasses. To "build back better," let those producers be part of an "all-of-the-above" clean, cheap and reliable all-America energy policy.
Which isn't the Joe Biden most people (including Democrats) likely thought they were getting. But it's the Joe Biden we have -- at least for now.
Public Health Director Barbara Ferrer noted that, due to the expense, "Very few of our specimens are genetically tested in this way." Statewide, only 5% of tests are run through genomic sequencing, according to California's top health officer. The rate is even less at the county level.
According to the other article I posted, the Pfizer vaccine is 2/3 less effective against the South African Variant and the Moderna Vaccine is 6.4 times less effective.
They found 34% of Covid-19 survivors received a diagnosis for a neurological or psychological condition within six months of their infection, according to the study published Tuesday in the journal Lancet Psychiatry.
The most common diagnosis was anxiety, found in 17% of those treated for Covid-19, followed by mood disorders, found in 14% of patients.
"That rate increased progressively as the severity of the Covid-19 illness increased. If we look at patients who were hospitalized that rate increased to 39%," said Maxime Taquet, an academic clinical fellow in psychiatry at the University of Oxford, and a co-author of the new study.
You may be wondering if the coronavirus variants have an impact on the effectiveness of our current vaccines.
From what we know so far, it appears that the current vaccines may be less effective for B.1.351, the variant first identified in South Africa. This is currently an area of ongoing, intense research.
Let's look at a snapshot of what some of the data says so far.
Large-scale clinical trials of the Pfizer-BioNTech vaccine found a vaccine effectiveness of 95 percent against the original version of the new coronavirus.
This vaccine is currently authorized for emergency use in the United States.
A recent study investigated the effectiveness of this vaccine for test viruses containing the mutations found in B.1.351. To do this, serum from individuals who had been vaccinated with the Pfizer-BioNTech vaccine was used.
Researchers found that this serum, which contains antibodies, was less effective against B.1.351. In fact, neutralization of test viruses containing all of the mutations present in B.1.351 was reduced by two-thirds.
What about B.1.1.7, the variant first seen in the U.K.?
A study similar to the one we've discussed above found that neutralization of test viruses with the spike protein of B.1.1.7 was only slightly lower than it was for earlier versions of the coronavirus.
The large-scale clinical trials on the Moderna vaccine determined that vaccine effectiveness was 94.1 percent against the original version of the new coronavirus.
Like the Pfizer-BioNTech vaccine, the Moderna vaccine has been authorized for emergency use in the United States.
A recent study looked into the effectiveness of the Moderna vaccine for the B.1.1.7 and B.1.351 variants. In order to do this, researchers used serum from individuals who had received the Moderna vaccine and test viruses containing the spike proteins from the variants.
It was found that test viruses with the B.1.1.7 spike protein were neutralized in a similar manner to earlier versions of the coronavirus.
However, neutralization of test viruses with the spike protein of B.1.351 was 6.4-fold lower.
Johnson & Johnson vaccine
The Johnson & Johnson vaccine is the third COVID-19 vaccine to be authorized for emergency use in the United States.
Unlike the Pfizer-BioNTech and Moderna vaccines, it only requires one dose.
This vaccine has yet to be tested against specific variants. However, large-scale clinical trials were performed in places where variants are circulating, such as South Africa and South America.
According to the data released from clinical trialsTrusted Source, the effectiveness of this vaccine 28 days after vaccination is:
66 percent effective overall
72 percent in the United States
66 percent effective in South America, where the P.1 variant is circulating
57 percent effective in South Africa, where the B.1.351 variant is circulating
85 percent effective at preventing severe COVID-19 symptoms across all geographical regions
The U.S. added almost 65,000 new Covid-19 cases on Saturday and remains on pace for the most weekly infections since the end of February. North Dakota has gone nine days without a Covid-19 fatality, the longest stretch since the first death there.
"I need to … I go to auditions, I work hard, I study scripts, I do my thing," she added.
Paris has certainly been doing her thing. Earlier this month, she starred in Stella McCartney's ad campaign for her new collection, featuring eco-conscious vegan-leather pieces.